

PHARMANUTRA S.P.A. JOINS THE “MSCI WORLD SMALL CAP” AND “FTSE ITALIA MID CAP” INDICES

***Reflecting the Group’s continuous growth and share-price performance, starting from December
PharmaNutra is included into two important indices for small caps.***

Pisa, 2 December 2021 – [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), a company specialising in mineral-based nutritional supplements and medical devices for muscles and joints, is pleased to inform its Shareholders that, since December 1st 2021, the Company has been included into the “MSCI World Small Cap Index” and that, from December 20th 2021, it will be also included into the “FTSE Italia Mid Cap” index.

Launched in January 2001, the “MSCI World Small Cap” index includes the major small cap companies listed in 23 countries among the most developed markets. With 4,419 companies, the index covers approximately 14% of the market capitalization (free-float) for each country.

The “FTSE Italia Mid Cap” index includes the first 60 Italian companies for capitalization which are not part of the FTSE MIB, and is the benchmark index for investments in Italian mid-cap stocks.

PharmaNutra’s admission to the “MSCI World Small Cap” and the “FTSE Italia Mid Cap” indices is a recognition at both national and international level for the Group, which has backed its business growth with impressive financial and market performance since its admission to trading. Currently, its share price is above 70 Euro (having risen 158% over the last year) and its market cap has exceeded 700 million Euro¹.

PharmaNutra S.p.A. Vice Chairman Roberto Lacorte comments: *“We are very proud to be included in these indices, which are the benchmark for the fastest growing small caps attracting interest also in the international markets. We consider these steps as a further improvement that reflects the achievement of the Group, confirming that PharmaNutra business model is becoming, day by day, a reference for the market. This recognition is an additional motivation for us to move ahead with new international development plans, backed by the solid results we reported this year and expect to consolidate in 2022.”*

¹ Borsa Italiana data on 30 November 2021.

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra, established in 2003, develops unique nutraceuticals and innovative medical devices, overseeing the entire production process from the proprietary raw materials to the finished product. PharmaNutra is the leading producer, with the SiderAL® trademark, of iron-based nutritional supplements, a field where it holds important patents on Sucrosomial® Technology, and is regarded as one of the top emerging players in medical devices for the rehabilitation of joint capacity thanks to the Cetilar brand. The effectiveness of its products has been demonstrated by extensive scientific evidence, including more than 120 published papers. In Italy, sales are conducted through a network of more than 160 medical representatives, who also handle exclusive marketing of PharmaNutra products to pharmacies and parapharmacies all over the country. International sales in more than 50 countries are managed through 37 partners selected from top pharmaceutical companies. Over the years, the Group has developed a specific intellectual property production and management strategy, based on integrated management of all components: proprietary raw materials, patents, trademarks and clinical data.

PharmaNutra.it

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

investorrelation@PharmaNutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com